NCT02892123 2024-11-27Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing CancersJazz PharmaceuticalsPhase 1 Completed279 enrolled
NCT01983501 2020-09-21A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast CancerSeagen Inc.Phase 1 Completed57 enrolled
NCT02025192 2020-06-04A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast CancerSeagen Inc.Phase 1 Completed60 enrolled